| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2100214 | Best Practice & Research Clinical Haematology | 2013 | 4 Pages |
Abstract
While it is logical to use hypomethylating agents to treat patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), trial results with azacitidine and decitabine have been inconsistent. Azacitidine confers a survival benefit in higher-risk MDS patients, while decitabine does not. Neither agent has demonstrated a survival advantage in older AML patients in prospective studies. Reasons for this are explored here along with a recommendation to reconsider clinical trial design endpoints.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Mikkael A. Sekeres,